[143例手术切除肺癌的DNA含量与癌基因（c-myc、L-myc、c-erbB-2）扩增的相关性及其与预后的关系]

[Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erbB-2) and correlation with prognosis in 143 cases of resected lung cancer].

作者信息

Chiba W, Sawai S, Hanawa T, Ishida H, Matsui T, Kosaba S, Watanabe S, Hatakenaka R, Matsubara Y, Funatsu T

机构信息

Respiratory Division, Kyoto-Katsura Hospital.

出版信息

Gan To Kagaku Ryoho. 1993 Apr;20(6):824-7.

PMID:8098200

Abstract

DNA content analysis using flow cytometry and amplification of c-myc, L-myc, and c-erbB-2 oncogenes in 143 cases of resected lung cancer were analyzed using the same specimen, and we examined the correlation with prognosis of DNA content and amplification of oncogenes. There were 54 DNA diploid cases (38%), 81 DNA aneuploid cases (57%) and 8 DNA multiploid cases. Analysis of oncogene amplification revealed 22 cases of c-myc, 4 cases of L-myc, and 22 cases of c-erbB-2. In curatively resected cases, the 5-year survival rate was 65% in 31 DNA diploid cases, and 36% in 40 DNA aneuploid cases. There was a statistically significant difference between the two groups (p < 0.02). However, in non-curatively resected cases, the 5-year survival rate was 11% in 23 DNA diploid cases, and 33% in 49 DNA aneuploid cases. There were no statistically significant differences among these groups. The correlation between DNA content and amplification of oncogenes was as follows. In DNA diploid cases, there were 4 cases of c-myc, and 6 cases of c-erbB-2. In DNA aneuploid cases, there were 15 cases of c-myc, 4 cases of L-myc, and 15 cases of c-erbB-2. In DNA multiploid cases, there were 3 cases of c-myc, and 1 cases of c-erbB-2. Amplification of oncogenes was seen more frequently in DNA aneuploid and multiploid cases than in DNA diploid cases. In 71 curative resected cases, the 5-year survival rate for amplified cases of c-myc (10 cases) was 0%, and that of cases with no amplification was 61% (no statistically significant difference). The 5-year survival rate for amplified cases of c-erbB-2 (10 cases) was 40%, against 52% for cases with no amplification. DNA content analysis using flow cytometry was more convenient than analysis of amplification of oncogenes, and reflects the prognosis of resected lung cancer better than oncogenes. There was no relation between DNA content and gene amplification.

摘要

采用相同标本对143例手术切除的肺癌进行了流式细胞术DNA含量分析以及c-myc、L-myc和c-erbB-2癌基因的扩增分析，并检测了DNA含量和癌基因扩增与预后的相关性。有54例DNA二倍体病例（38%），81例DNA非整倍体病例（57%）和8例DNA多倍体病例。癌基因扩增分析显示，c-myc有22例，L-myc有4例，c-erbB-2有22例。在根治性切除病例中，31例DNA二倍体病例的5年生存率为65%，40例DNA非整倍体病例的5年生存率为36%。两组之间存在统计学显著差异（p<0.02）。然而，在非根治性切除病例中，23例DNA二倍体病例的5年生存率为11%，49例DNA非整倍体病例的5年生存率为33%。这些组之间无统计学显著差异。DNA含量与癌基因扩增的相关性如下。在DNA二倍体病例中，c-myc有4例，c-erbB-2有6例。在DNA非整倍体病例中，c-myc有15例，L-myc有4例，c-erbB-2有15例。在DNA多倍体病例中，c-myc有3例，c-erbB-2有1例。癌基因扩增在DNA非整倍体和多倍体病例中比在DNA二倍体病例中更常见。在71例根治性切除病例中，c-myc扩增病例（10例）的5年生存率为0%，无扩增病例的5年生存率为61%（无统计学显著差异）。c-erbB-2扩增病例（10例）的5年生存率为40%，无扩增病例为52%。采用流式细胞术进行DNA含量分析比癌基因扩增分析更方便，且比癌基因能更好地反映手术切除肺癌的预后。DNA含量与基因扩增之间无关联。